Form 10-Q Intellia Therapeutics, For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech stocks weigh on Wall Street as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
Intellia Therapeutics (NTLA) PT Lowered to $29 at Citi
May 9, 2024 4:40 PM EDTCiti analyst David Lebowitz lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $29.00 (from $31.00) while maintaining a Neutral rating.
The analyst comments "On the 1Q24 call, Intellia announced a new NTLA-2001 Ph3 trial in ATTR-PN (starting 2024). NTLA-2001s Ph3 MAGNITUDE... More
